Get the Stockscreener App
1.83
3.17%
-0.06
Lexaria Bioscience Corp stock is traded at $1.83, with a volume of 45,116.
It is down -3.17% in the last 24 hours and down -18.30% over the past month.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
See More
Previous Close:
$1.89
Open:
$1.91
24h Volume:
45,116
Relative Volume:
0.25
Market Cap:
$33.17M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-4.1591
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
+3.39%
1M Performance:
-18.30%
6M Performance:
-49.03%
1Y Performance:
-7.58%
1-Day Range:
$1.8201
$1.911
1-Week Range:
$1.72
$1.911
52-Week Range:
$1.62
$6.85
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.83 | 33.17M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.76 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.15 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1 - TipRanks
Revolutionary GLP-1 Study: Lexaria's DehydraTECH Goes Head-to-Head with Rybelsus - StockTitan
Lexaria Advances Human Study on Diabetes and Weight Loss Treatment - TipRanks
Revolutionary GLP-1 Breakthrough: Lexaria's Technology Matches Zepbound Efficacy with Fewer Side Effects - StockTitan
Lexaria reports promising drug delivery study results - Investing.com India
Research Analysts Issue Forecasts for LEXX Q2 Earnings - Defense World
Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024 - TipRanks
Lexaria Releases Annual Letter from the CEO - WICZ
GLP-1 Game-Changer: This Small Biotech Found How to Slash Semaglutide Side Effects by 60% - StockTitan
What is Zacks Small Cap’s Estimate for LEXX Q4 Earnings? - Defense World
LEXX: IRB Approval Clears Way for GLP-1 Study #5 - Yahoo Finance
HC Wainwright Has Lowered Expectations for Lexaria Bioscience (NASDAQ:LEXX) Stock Price - Defense World
Lexaria Bioscience stock target cut to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock target cut to $7 at H.C. Wainwright - Investing.com
Lexaria Bioscience Holds Successful Shareholder Meeting; Votes in New Directors and Approves Proposals - Defense World
Lexaria Bioscience shareholders approve board and auditor selections - Investing.com
Lexaria Bioscience Advances with Human Study for Oral Liraglutide - TipRanks
LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval - WICZ
Lexaria Gets Green Light for Oral Weight Loss Drug Trial, Aims to Replace Saxenda Injections - StockTitan
Lexaria’s Oral Drug Shows Promising Results Against Eli Lilly’s Injection - TipRanks
Lexaria's Oral GLP-1 Drug Shows 47% Fewer Side Effects Than Injectable Zepbound in Clinical Study - StockTitan
Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2024 - Marketscreener.com
Lexaria Bioscience Earnings Analysis: Q1 Recap - Benzinga
Lexaria Bioscience Corp. (LEXX) reports earnings - Quartz
NRx Pharmaceuticals (NASDAQ:NRXP) and Lexaria Bioscience (NASDAQ:LEXX) Head to Head Contrast - Defense World
Lexaria Bioscience Announces Executive Management Agreement ChangesLexaria Bioscience Corp. (OTCMKTS:LXRP) recently disclosed key alterations to its Executive Management Agreement in a current report filed with the Securities and Exchange Com - Defense World
HighTower Advisors LLC Takes Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
H.C. Wainwright maintains Buy rating on Lexaria Bioscience stock By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains Buy rating on Lexaria Bioscience stock - Investing.com
Lexaria Bioscience Corp. (NASDAQ:LEXX) Shares Bought by XTX Topco Ltd - Defense World
Lexaria Bioscience Launches Key Phase 1b Trial Testing DehydraTECH Enhancement of GLP-1 Drugs - StockTitan
Lexaria Bioscience finalizes clinical study agreement By Investing.com - Investing.com South Africa
Lexaria Bioscience finalizes clinical study agreement - Investing.com
Lexaria forms scientific advisory board to enhance drug delivery tech - Investing.com
Lexaria Bioscience Forms Elite Scientific Advisory Board with Harvard Medical School Expert - StockTitan
Lexaria Bioscience Taps Harvard Medical Expert to Accelerate GLP-1 & Hypertension Drug Development - StockTitan
Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide - Yahoo Finance
Lexaria's Oral GLP-1 Drug Shows Promise: Plans First Human Trial After Beating Rybelsus in Animal Study - StockTitan
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 - Yahoo Finance
LEXX (Lexaria Bioscience) Enterprise Value : $38.78 Mil (As of Dec. 06, 2024) - GuruFocus.com
LEXX: Phase I Start Imminent - Yahoo Finance
Q1 EPS Forecast for Lexaria Bioscience Decreased by Analyst - Defense World
LEXX (Lexaria Bioscience) Market Cap : $47.13 Mil (As of Dec. 03, 2024) - GuruFocus.com
Insider Buying: Richard Christopher Acquires 50,000 Shares of Le - GuruFocus.com
Lexaria Bioscience CEO buys $118,391 in shares By Investing.com - Investing.com Nigeria
Lexaria Bioscience CEO buys $118,391 in shares - Investing.com
Lexaria Bioscience (NASDAQ:LEXX) Receives Buy Rating from HC Wainwright - Defense World
Lexaria Bioscience keeps stock target with Buy rating on financial results - Investing.com
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexaria Bioscience Corp Stock (LEXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHRISTOPHER RICHARD | Chief Executive Officer |
Dec 02 '24 |
Buy |
2.24 |
22,828 |
51,217 |
22,828 |
| TURKEL CATHERINE C. | Director |
Aug 12 '24 |
Buy |
3.13 |
1,600 |
5,008 |
3,100 |
| Carle Vanessa | Secretary |
Jul 31 '24 |
Sale |
4.00 |
2,567 |
10,268 |
0 |
| Carle Vanessa | Secretary |
May 14 '24 |
Option Exercise |
1.15 |
2,500 |
2,875 |
2,567 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):